KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Payables (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Payables data on record, last reported at $227.5 million in Q4 2025.

  • For Q4 2025, Payables rose 15.25% year-over-year to $227.5 million; the TTM value through Dec 2025 reached $227.5 million, up 15.25%, while the annual FY2025 figure was $227.5 million, 15.25% up from the prior year.
  • Payables reached $227.5 million in Q4 2025 per EW's latest filing, up from $165.0 million in the prior quarter.
  • Across five years, Payables topped out at $861.1 million in Q2 2021 and bottomed at $139.5 million in Q3 2021.
  • Average Payables over 5 years is $248.9 million, with a median of $186.6 million recorded in 2023.
  • Peak YoY movement for Payables: crashed 83.03% in 2021, then rose 23.05% in 2023.
  • A 5-year view of Payables shows it stood at $204.5 million in 2021, then fell by 1.27% to $201.9 million in 2022, then dropped by 7.58% to $186.6 million in 2023, then increased by 5.79% to $197.4 million in 2024, then grew by 15.25% to $227.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $227.5 million in Q4 2025, $165.0 million in Q3 2025, and $162.1 million in Q2 2025.